United States· US:70842-240_32d9ddc4-232f-45f9-ab7d-a34c46cf9b1c
REZZAYO
A medicinal product containing rezafungin, registered in United States by Melinta Therapeutics, LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- REZAFUNGIN
- Manufacturer
- Melinta Therapeutics, LLC
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc1170842-240-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rezafungin in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRezzayo 200 mgMundipharma
- SwitzerlandRezzayo 200 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMundipharma Medical Company, Hamilton, Bermuda, Basel Branch
- CzechiaREZZAYOMundipharma Gesellschaft mit beschränkter Haftung, FRANKFURT
- SpainREZZAYO 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMundipharma Gmbh
- FinlandREZZAYOMundipharma GmbH
- FranceREZZAYO 200 mg, poudre pour solution à diluer pour perfusionMUNDIPHARMA (ALLEMAGNE)
- United KingdomRezzayo 200mg powder for concentrate for solution for infusion vialsNapp Pharmaceuticals Ltd
- IrelandREZZAYO 200 mg powder for concentrate for solution for infusionMundipharma GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rezzayo
- Liechtenstein · Rezzayo
- Norway · Rezzayo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e72bc48d-1e65-4c1b-82cd-ee96571991a4 GET /v1/drugs/e72bc48d-1e65-4c1b-82cd-ee96571991a4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "200",
"substance": "REZAFUNGIN",
"productndc": "70842-240",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA217417",
"marketing_category": "NDA"
}See everything about rezafungin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.